ID   92-1 [Human uveal melanoma]
AC   CVCL_8607
SY   92_1; 92.1; 921
DR   CLDB; cl7221
DR   cancercelllines; CVCL_8607
DR   Cosmic; 848328
DR   Cosmic; 899893
DR   Cosmic; 916137
DR   Cosmic; 986619
DR   Cosmic; 1320371
DR   Cosmic; 1628394
DR   Cosmic; 1669117
DR   Cosmic; 2036703
DR   Cosmic; 2163829
DR   DepMap; ACH-001441
DR   ECACC; 13012458
DR   ESTDAB; ESTDAB-127
DR   GEO; GSM276761
DR   ICLC; HTL12001
DR   PRIDE; PXD032215
DR   Wikidata; Q54605663
RX   PubMed=7622289;
RX   PubMed=15714118;
RX   PubMed=16772116;
RX   PubMed=17487557;
RX   PubMed=19340423;
RX   PubMed=22236444;
RX   PubMed=22383533;
RX   PubMed=23849826;
RX   PubMed=23851445;
RX   PubMed=24994677;
RX   PubMed=28018010;
RX   PubMed=32430489;
RX   PubMed=36164296;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Doubling time: 58 hours (PubMed=7622289); 38 hours (PubMed=24994677).
CC   HLA typing: A*02:01,03:01; B*44:02,51:01; C*05:01,14:02 (PubMed=28018010).
CC   Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000375955; Zygosity=Heterozygous (PubMed=22236444; PubMed=22383533; PubMed=23851445; PubMed=24994677; PubMed=28018010).
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Eye, uvea; UBERON=UBERON_0001768.
ST   Source(s): DepMap=ACH-001441; ECACC=13012458; ESTDAB=ESTDAB-127; PubMed=22236444; PubMed=24994677; PubMed=28018010
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 10,11 (ESTDAB=ESTDAB-127; PubMed=24994677)
ST   D13S317: 11,12 (DepMap=ACH-001441; ECACC=13012458; PubMed=22236444)
ST   D16S539: 11,12 (PubMed=22236444; PubMed=24994677)
ST   D16S539: 12 (DepMap=ACH-001441; ECACC=13012458)
ST   D18S51: 12,13
ST   D21S11: 30
ST   D3S1358: 14,15
ST   D5S818: 9,11 (DepMap=ACH-001441; ECACC=13012458; PubMed=22236444; PubMed=24994677)
ST   D5S818: 12,13 (ESTDAB=ESTDAB-127)
ST   D7S820: 10,11 (DepMap=ACH-001441; ECACC=13012458; PubMed=22236444; PubMed=24994677)
ST   D7S820: 11 (ESTDAB=ESTDAB-127)
ST   D8S1179: 15
ST   FGA: 21,23
ST   Penta D: 9,11
ST   Penta E: 12,14
ST   TH01: 9,9.3
ST   TPOX: 8,9
ST   vWA: 16
DI   NCIt; C7712; Uveal melanoma
DI   ORDO; Orphanet_39044; Uveal melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_C300 ! 92-2
SX   Female
AG   76Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 35
//
RX   PubMed=7622289; DOI=10.1002/ijc.2910620208;
RA   De Waard-Siebinga I., Blom D.-J.R., Griffioen M., Schrier P.I.,
RA   Hoogendoorn E., Beverstock G.C., Danen E.H.J., Jager M.J.;
RT   "Establishment and characterization of an uveal-melanoma cell line.";
RL   Int. J. Cancer 62:155-161(1995).
//
RX   PubMed=15714118; DOI=10.1097/00008390-200502000-00006;
RA   Lopez-Velasco R., Morilla-Grasa A., Saornil-Alvarez M.A.,
RA   Ordonez J.L., Blanco G., Rabano G., Fernandez N., Almaraz A.;
RT   "Efficacy of five human melanocytic cell lines in experimental rabbit
RT   choroidal melanoma.";
RL   Melanoma Res. 15:29-37(2005).
//
RX   PubMed=16772116; DOI=10.1016/j.cancergencyto.2005.11.016;
RA   White J.S., Becker R.L., McLean I.W., Director-Myska A.E., Nath J.;
RT   "Molecular cytogenetic evaluation of 10 uveal melanoma cell lines.";
RL   Cancer Genet. Cytogenet. 168:11-21(2006).
//
RX   PubMed=17487557; DOI=10.1007/s10585-007-9072-z;
RA   Marshall J.-C., Nantel A., Blanco P., Ash J., Cruess S.R.,
RA   Burnier M.N. Jr.;
RT   "Transcriptional profiling of human uveal melanoma from cell lines to
RT   intraocular tumors to metastasis.";
RL   Clin. Exp. Metastasis 24:353-362(2007).
//
RX   PubMed=19340423; DOI=10.1007/s00262-009-0701-z;
RA   Mendez R., Aptsiauri N., Del Campo A., Maleno I., Cabrera T.,
RA   Ruiz-Cabello Osuna F., Garrido F., Garcia-Lora A.;
RT   "HLA and melanoma: multiple alterations in HLA class I and II
RT   expression in human melanoma cell lines from ESTDAB cell bank.";
RL   Cancer Immunol. Immunother. 58:1507-1515(2009).
//
RX   PubMed=22236444; DOI=10.1111/j.1755-148X.2012.00971.x;
RA   Griewank K.G., Yu X.-X., Khalili J.S., Sozen M.M., Stempke-Hale K.,
RA   Bernatchez C., Wardell S., Bastian B.C., Woodman S.E.;
RT   "Genetic and molecular characterization of uveal melanoma cell
RT   lines.";
RL   Pigment Cell Melanoma Res. 25:182-187(2012).
//
RX   PubMed=22383533; DOI=10.1158/1535-7163.MCT-11-0676;
RA   Dutton-Regester K., Irwin D., Hunt P., Aoude L.G., Tembe V.,
RA   Pupo G.M., Lanagan C., Carter C.D., O'Connor L., O'Rourke M.,
RA   Scolyer R.A., Mann G.J., Schmidt C.W., Herington A., Hayward N.K.;
RT   "A high-throughput panel for identifying clinically relevant mutation
RT   profiles in melanoma.";
RL   Mol. Cancer Ther. 11:888-897(2012).
//
RX   PubMed=23849826; DOI=10.1016/j.ejca.2013.06.011;
RA   Amaro A., Mirisola V., Angelini G., Musso A., Tosetti F.I.,
RA   Esposito A.I., Perri P., Lanza F.B., Nasciuti F., Mosci C., Puzone R.,
RA   Salvi S., Truini M., Poggi A., Pfeffer U.;
RT   "Evidence of epidermal growth factor receptor expression in uveal
RT   melanoma: inhibition of epidermal growth factor-mediated signalling
RT   by gefitinib and cetuximab triggered antibody-dependent cellular
RT   cytotoxicity.";
RL   Eur. J. Cancer 49:3353-3365(2013).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//
RX   PubMed=24994677; DOI=10.1016/j.molonc.2014.06.004;
RA   Amirouchene-Angelozzi N., Nemati F., Gentien D., Nicolas A.,
RA   Dumont A., Carita G., Camonis J., Desjardins L., Cassoux N.,
RA   Piperno-Neumann S., Mariani P., Sastre X., Decaudin D.,
RA   Roman-Roman S.;
RT   "Establishment of novel cell lines recapitulating the genetic
RT   landscape of uveal melanoma and preclinical validation of mTOR as a
RT   therapeutic target.";
RL   Mol. Oncol. 8:1508-1520(2014).
//
RX   PubMed=28018010;
RA   Jager M.J., Bermudez Magner J.A., Ksander B.R., Dubovy S.R.;
RT   "Uveal melanoma cell lines: where do they come from? (an American
RT   Ophthalmological Society thesis).";
RL   Trans. Am. Ophthalmol. Soc. 114:T5-T5(2016).
//
RX   PubMed=32430489; DOI=10.1158/1535-7163.MCT-19-1016;
RA   Teh J.L.F., Purwin T.J., Han A., Chua V., Patel P., Baqai U., Liao C.,
RA   Bechtel N., Sato T., Davies M.A., Aguirre-Ghiso J.A., Aplin A.E.;
RT   "Metabolic adaptations to MEK and CDK4/6 cotargeting in uveal
RT   melanoma.";
RL   Mol. Cancer Ther. 19:1719-1726(2020).
//
RX   PubMed=36164296; DOI=10.1016/j.dib.2022.108592;
RA   Fei X.-F., Xie X.-T., Ji X.-Y., Tian H.-Y., Sun F., Jiang D.-Y.,
RA   Wang Z.-M., Huang Q.;
RT   "Quantitative proteomic dataset of whole protein in three melanoma
RT   samples of 92.1, 92.1-A and 92.1-B.";
RL   Data Brief 45:108592.1-108592.7(2022).
//